Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Sep 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 12 Apr 2017 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017.